New shingles vaccine gets preferential recommendation from ATAGI and NCIRS

But it’s also more expensive than the incumbent

This educational activity was developed by ADG at the request of and with funding from GSK.

two vaccines

Australia’s newest shingles vaccine is now “the preferred zoster vaccine” for adults 50 years and over, according to updated guidance from the National Centre for Immunisation Research and Surveillance (NCIRS) and the Australian Technical Advisory Group on Immunisation (ATAGI).

The guidance states Shingrix (recombinant varicella zoster virus glycoprotein E antigen - AS01B